A Validation Study of an AFP Whole Blood One-Step Rapid Home Detection Kit in Screening for HCC

Abstract

Hepatocellular carcinoma (HCC) is still a main cause of cancer-related death in China. Early detection and diagnosis may increase the likelihood of curing the HCC. Dynamic monitoring AFP levels can be a surveillance indicator to detect early-stage HCC. However, to our disappointment, most people with chronic liver diseases do not test AFP levels regularly for a variety of reasons. The AFP whole blood one-step rapid home detection kit, with a high sensetivity and specifitivity, can be used to test AFP levels periodically by community residents with chronic hepatitis B. This can make it possible to detect, diagnose and treat HCC much earlier. This research aimed to verify the previous studies on the kit’s performance, characteristic, application and usage. The result was that the positive accordance rate and the negative accordance rate of the AFP whole blood one-step rapid home detection kit and ARCHITECT AFP were 96.77% (90/93) and 97.94% (95/97). The rapid home detection kit is introduced and popularized to apply into screening and diagnosing early-stage HCC in community individuals with chronic liver diseases, which is meaningful to achieving the goal of reducing mortality in patients with HCC to a great extent.